<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d14" origId="Irinotecan"><sentence id="DrugDDI.d14.s0" origId="s0" text="The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects."><entity charOffset="23-32" id="DrugDDI.d14.s0.e0" origId="s0.p1" text="CAMPTOSAR" type="drug"/><entity charOffset="112-139" id="DrugDDI.d14.s0.e1" origId="s0.p11" text="other antineoplastic agents" type="drug"/><pair e1="DrugDDI.d14.s0.e0" e2="DrugDDI.d14.s0.e1" id="DrugDDI.d14.s0.p0" interaction="true"/></sentence><sentence id="DrugDDI.d14.s1" origId="s1" text="Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR."><entity charOffset="149-158" id="DrugDDI.d14.s1.e0" origId="s1.p26" text="CAMPTOSAR" type="drug"/></sentence><sentence id="DrugDDI.d14.s2" origId="s2" text="The concurrent administration of CAMPTOSAR with irradiation has not been adequately studied and is not recommended."><entity charOffset="33-42" id="DrugDDI.d14.s2.e0" origId="s2.p28" text="CAMPTOSAR" type="drug"/><negationtags>&lt;xcope&gt;The concurrent administration of CAMPTOSAR with irradiation has &lt;cue&gt;not&lt;/cue&gt; been adequately studied &lt;/xcope&gt; and is &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; recommended&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d14.s3" origId="s3" text="Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect."><entity charOffset="56-65" id="DrugDDI.d14.s3.e0" origId="s3.p45" text="CAMPTOSAR" type="drug"/><entity charOffset="113-126" id="DrugDDI.d14.s3.e1" origId="s3.p51" text="dexamethasone" type="drug"/><entity charOffset="130-140" id="DrugDDI.d14.s3.e2" origId="s3.p52" text="antiemetic" type="drug"/><pair e1="DrugDDI.d14.s3.e0" e2="DrugDDI.d14.s3.e1" id="DrugDDI.d14.s3.p0" interaction="false"/><pair e1="DrugDDI.d14.s3.e0" e2="DrugDDI.d14.s3.e2" id="DrugDDI.d14.s3.p1" interaction="false"/><pair e1="DrugDDI.d14.s3.e1" e2="DrugDDI.d14.s3.e2" id="DrugDDI.d14.s3.p2" interaction="false"/></sentence><sentence id="DrugDDI.d14.s4" origId="s4" text="However, serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia."><negationtags>However, &lt;xcope&gt; serious opportunistic infections have &lt;cue&gt;not&lt;/cue&gt; been observed&lt;/xcope&gt;, and &lt;xcope&gt;&lt;cue&gt;no&lt;/cue&gt; complications have specifically been attributed&lt;/xcope&gt; to lymphocytopenia.</negationtags></sentence><sentence id="DrugDDI.d14.s5" origId="s5" text="Hyperglycemia has also been reported in patients receiving CAMPTOSAR."><entity charOffset="59-68" id="DrugDDI.d14.s5.e0" origId="s5.p79" text="CAMPTOSAR" type="drug"/></sentence><sentence id="DrugDDI.d14.s6" origId="s6" text="Usually, this has been observed in patients with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR."><entity charOffset="142-151" id="DrugDDI.d14.s6.e0" origId="s6.p92" text="CAMPTOSAR" type="drug"/></sentence><sentence id="DrugDDI.d14.s7" origId="s7" text="It is probable that dexamethasone, given as antiemetic prophylaxis, contributed to hyperglycemia in some patients."><entity charOffset="20-33" id="DrugDDI.d14.s7.e0" origId="s7.p96" text="dexamethasone" type="drug"/><entity charOffset="44-54" id="DrugDDI.d14.s7.e1" origId="s7.p98" text="antiemetic" type="drug"/><pair e1="DrugDDI.d14.s7.e0" e2="DrugDDI.d14.s7.e1" id="DrugDDI.d14.s7.p0" interaction="false"/></sentence><sentence id="DrugDDI.d14.s8" origId="s8" text="The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients)."><entity charOffset="115-131" id="DrugDDI.d14.s8.e0" origId="s8.p113" text="prochlorperazine" type="drug"/><entity charOffset="168-177" id="DrugDDI.d14.s8.e1" origId="s8.p117" text="CAMPTOSAR" type="drug"/><entity charOffset="194-199" id="DrugDDI.d14.s8.e2" origId="s8.p120" text="drugs" type="drug"/><pair e1="DrugDDI.d14.s8.e0" e2="DrugDDI.d14.s8.e1" id="DrugDDI.d14.s8.p0" interaction="true"/><pair e1="DrugDDI.d14.s8.e0" e2="DrugDDI.d14.s8.e2" id="DrugDDI.d14.s8.p1" interaction="false"/><pair e1="DrugDDI.d14.s8.e1" e2="DrugDDI.d14.s8.e2" id="DrugDDI.d14.s8.p2" interaction="false"/></sentence><sentence id="DrugDDI.d14.s9" origId="s9" text="The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies."><entity charOffset="82-98" id="DrugDDI.d14.s9.e0" origId="s9.p135" text="prochlorperazine" type="drug"/></sentence><sentence id="DrugDDI.d14.s10" origId="s10" text="It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied."><entity charOffset="26-34" id="DrugDDI.d14.s10.e0" origId="s10.p144" text="laxative" type="drug"/><entity charOffset="59-68" id="DrugDDI.d14.s10.e1" origId="s10.p146" text="CAMPTOSAR" type="drug"/><pair e1="DrugDDI.d14.s10.e0" e2="DrugDDI.d14.s10.e1" id="DrugDDI.d14.s10.p0" interaction="false"/><negationtags>It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, &lt;xcope&gt;but this has &lt;cue&gt;not&lt;/cue&gt; been studied&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d14.s11" origId="s11" text="In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea."><entity charOffset="94-103" id="DrugDDI.d14.s11.e0" origId="s11.p166" text="CAMPTOSAR" type="drug"/><entity charOffset="140-149" id="DrugDDI.d14.s11.e1" origId="s11.p170" text="diuretics" type="drug"/><entity charOffset="169-178" id="DrugDDI.d14.s11.e2" origId="s11.p172" text="CAMPTOSAR" type="drug"/><pair e1="DrugDDI.d14.s11.e0" e2="DrugDDI.d14.s11.e1" id="DrugDDI.d14.s11.p0" interaction="false"/><pair e1="DrugDDI.d14.s11.e0" e2="DrugDDI.d14.s11.e2" id="DrugDDI.d14.s11.p1" interaction="false"/><pair e1="DrugDDI.d14.s11.e1" e2="DrugDDI.d14.s11.e2" id="DrugDDI.d14.s11.p2" interaction="true"/></sentence><sentence id="DrugDDI.d14.s12" origId="s12" text="Drug-Laboratory Test Interactions There are no known interactions between CAMPTOSAR and laboratory tests."><entity charOffset="74-83" id="DrugDDI.d14.s12.e0" origId="s12.p183" text="CAMPTOSAR" type="drug"/><negationtags>Drug-Laboratory Test Interactions There are &lt;xcope&gt;&lt;cue&gt;no&lt;/cue&gt; known interactions between CAMPTOSAR and laboratory tests&lt;/xcope&gt;.</negationtags></sentence></document>